Table 1.
Clinical & Socioeconomic Factors by Racial Groups.
| Continuous Variables | AA (n = 96) |
EA (n = 76) |
p-value1 |
|---|---|---|---|
| Median [IQR] | Median [IQR] | ||
| Age, years | 61.5 [57.5, 67.0] | 62.0 [59.0, 66.8] | 0.78 |
| BMI, kg/m2 | 28.1 [25.8, 30.8] | 27.4 [26.0, 29.9] | 0.34 |
| West African Ancestry, % | 78.6% [67.5%, 85.8%] | 4.0% [1.7%, 6.6%] | <0.001 |
| PSA, ng/ml | 6.0 [4.5, 8.9] | 4.6 [3.85, 7.14] | <0.001 |
| PSA density, ng/cm3 | 0.16 [0.10, 0.24] | 0.12 [0.08, 0.19] | <0.001 |
| CAPRA | 3.0 [2.0, 4.0] | 2.0 [1.0, 3.0] | <0.001 |
| GPS | 29.5 [23.3, 37.5] | 27.0 [23.0, 35.0] | 0.27 |
| Number of Positive Cores | 3.0 [2.0, 6.0] | 2/0 [ 1.0, 4.0] | 0.004 |
| Percent of Positive Cores | 27.9% [16.7%, 45.7%] | 17/4% [8.3%, 3.3%] | 0.001 |
| Categorical Variables | AA n (%) |
EA n (%) |
p-value2 |
| Pre-orostatectomy | |||
| Current Smoking | 24/96 (25.0) | 2/74 (2.7) | <0.001 |
| High school completion | 76/95 (80.0) | 59/74 (79.7) | 0.96 |
| Income < $30,000/year | 24/95 (25.2) | 11/71 (15.5) | 0.13 |
| FHx of PCa | 27/96 (28.1) | 16/76 (21.1) | 0.35 |
| Abnormal DRE | 17/96 (17.7) | 19/76 (25.0) | 0.24 |
| 5α-reductase inhibitor use | 1/96 (1.0) | 3 (3.9) | 0.19 |
| NCCN Risk Group | |||
| Very Low/Low | 31 (32.3) | 38 (50.0) | 0.02 |
| Favorable Intermediate | 35 (36.5) | 32 (42.1) | 0.45 |
| Unfavorable Intermediate | 30 (31.2) | 6 (7.9) | <0.001 |
| Post-prostatectomy | |||
| Adverse Pathology | 24/96 (25.0) | 22/76 (28.9) | 0.56 |
| Pathology Staging | |||
| T2a-T2b | 8 (8.3) | 6 (7.9) | 0.97 |
| T2c | 71 (74.0) | 54 (71.1) | 0.67 |
| T3a-T3b | 17 (17.7) | 16 (21.0) | 0.58 |
1
Using Mann-Whitney tests
2
Using χ2 tests; Bold type indicates p values <0.05
Abbreviations: AA: African American; EA: European American; BMI: Body Mass Index; PSA: Prostate Specific Antigen; CAPRA: Cancer of the Prostate Risk Assessment; GPS: Genomic Prostate Score; FHx of PCa: 1st degree Family History of Prostate cancer; DRE: digital rectal examination; NCCN: National Comprehensive Cancer Network.